Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KMDA Kamada	$7.71 -2.4%	$6.91	$4.83 ▼ $9.16	$443.40M	0.94	96,672 shs	106,214 shs
PLRX Pliant Therapeutics	$1.25 -3.8%	$1.43	$1.10 ▼ $16.10	$76.74M	1.35	1.16 million shs	10.87 million shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.40 ▼ $6.65	$381.02M	0.9	3.58 million shs	N/A
SIGA Siga Technologies	$6.46 -1.5%	$6.06	$4.95 ▼ $12.83	$461.50M	0.93	718,920 shs	915,801 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KMDA Kamada	0.00%	+7.08%	+13.05%	+16.64%	+55.44%
PLRX Pliant Therapeutics	0.00%	-2.34%	-9.42%	-7.41%	-88.37%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	0.00%	+42.02%
SIGA Siga Technologies	0.00%	+5.56%	+7.49%	+17.88%	-14.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KMDA Kamada	4.0414 of 5 stars	3.4	3.0	0.0	3.3	1.7	3.1
PLRX Pliant Therapeutics	4.1955 of 5 stars	3.0	4.0	4.7	2.2	1.7	0.6
RVNC Revance Therapeutics	2.6916 of 5 stars	3.1	0.0	4.7	0.0	1.7	0.6
SIGA Siga Technologies	1.504 of 5 stars	0.0	1.0	0.0	2.1	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KMDA Kamada	2.75	Moderate Buy	$14.67	90.23% Upside
PLRX Pliant Therapeutics	2.00	Hold	$13.31	965.00% Upside
RVNC Revance Therapeutics	2.13	Hold	$8.45	131.51% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PLRX, SIGA, KMDA, and RVNC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KMDA Kamada	$160.95M	2.75	$0.49 per share	15.68	$4.51 per share	1.71
PLRX Pliant Therapeutics	$1.58M	48.57	N/A	N/A	$5.00 per share	0.25
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
SIGA Siga Technologies	$138.72M	3.33	$0.84 per share	7.72	$3.02 per share	2.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KMDA Kamada	$14.46M	$0.29	26.59	24.09	0.93	9.60%	6.31%	4.43%	8/13/2025 (Estimated)
PLRX Pliant Therapeutics	-$210.30M	-$3.61	N/A	N/A	N/A	N/A	-67.56%	-52.54%	8/6/2025 (Estimated)
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	8/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	9.64	5.17	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)

Latest PLRX, SIGA, KMDA, and RVNC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Latest PLRX, SIGA, KMDA, and RVNC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA Siga Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KMDA Kamada	N/A	3.30	1.93
PLRX Pliant Therapeutics	N/A	11.03	11.03
RVNC Revance Therapeutics	N/A	4.12	3.05
SIGA Siga Technologies	N/A	8.40	6.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KMDA Kamada	20.38%
PLRX Pliant Therapeutics	97.30%
RVNC Revance Therapeutics	97.70%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
KMDA Kamada	36.10%
PLRX Pliant Therapeutics	6.40%
RVNC Revance Therapeutics	5.10%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	57.46 million	Optionable
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable

PLRX, SIGA, KMDA, and RVNC Headlines

Recent News About These Companies

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

Investors Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

June 26, 2025 | marketbeat.com

New nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactors

June 25, 2025 | msn.com

General Atomics Achieves Another Milestone in Silicon Carbide Composite Nuclear Fuel Rod Technology

June 24, 2025 | indystar.comI

Here's Why Siga Technologies Inc. (SIGA) Fell More Than Broader Market

June 20, 2025 | zacks.com

Undiscovered Gems In US Market Including SIGA Technologies And 2 Other Small Caps

June 17, 2025 | finance.yahoo.com

Bank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

June 16, 2025 | marketbeat.com

Why Siga Technologies Inc. (SIGA) Dipped More Than Broader Market Today

June 13, 2025 | zacks.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Harbor Capital Advisors Inc.

June 13, 2025 | marketbeat.com

Traders Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)

June 12, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Short Interest Down 12.5% in May

June 4, 2025 | marketbeat.com

Traders Purchase Large Volume of SIGA Technologies Call Options (NASDAQ:SIGA)

May 30, 2025 | marketbeat.com

We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings

May 16, 2025 | finance.yahoo.com

Undiscovered Gems in the US Market for May 2025

May 15, 2025 | finance.yahoo.com

SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)

May 10, 2025 | finance.yahoo.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call Transcript

May 9, 2025 | msn.com

SIGA Reports Financial Results for Three Months Ended March 31, 2025

May 8, 2025 | globenewswire.com

Calculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

May 2, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors

May 1, 2025 | zacks.com

SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results

May 1, 2025 | globenewswire.com

Chiliz joins SIGA to help drive integrity in sport

April 30, 2025 | en.as.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, SIGA, KMDA, and RVNC Company Descriptions

Kamada NASDAQ:KMDA

$7.71 -0.19 (-2.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.86 +0.15 (+1.89%)

As of 04:05 AM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Pliant Therapeutics NASDAQ:PLRX

$1.25 -0.05 (-3.85%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.33 +0.08 (+6.72%)

As of 05:15 AM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)

As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Siga Technologies NASDAQ:SIGA

$6.46 -0.10 (-1.52%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.58 +0.12 (+1.86%)

As of 04:28 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time